Stefan Alig

1.8k total citations
32 papers, 240 citations indexed

About

Stefan Alig is a scholar working on Pathology and Forensic Medicine, Cancer Research and Oncology. According to data from OpenAlex, Stefan Alig has authored 32 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 20 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Stefan Alig's work include Lymphoma Diagnosis and Treatment (21 papers), Cancer Genomics and Diagnostics (19 papers) and Genetic factors in colorectal cancer (6 papers). Stefan Alig is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Cancer Genomics and Diagnostics (19 papers) and Genetic factors in colorectal cancer (6 papers). Stefan Alig collaborates with scholars based in United States, Germany and France. Stefan Alig's co-authors include Martin Dreyling, Joachim Pircher, Florian Krötz, Hanna Mannell, Ash A. Alizadeh, Sarah Haebe, Oliver Weigert, Elisabeth Koch, Benedikt A. Aulinger and David M. Kurtz and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stefan Alig

24 papers receiving 236 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan Alig United States 10 126 115 59 56 39 32 240
Sebastian Ziegler Germany 3 189 1.5× 99 0.9× 48 0.8× 38 0.7× 93 2.4× 4 287
Hilka Rauert‐Wunderlich Germany 9 124 1.0× 132 1.1× 43 0.7× 87 1.6× 62 1.6× 16 262
Chelsea Mullins United States 7 98 0.8× 114 1.0× 105 1.8× 99 1.8× 24 0.6× 17 265
Álvaro Eguileor United States 6 109 0.9× 76 0.7× 31 0.5× 109 1.9× 46 1.2× 8 251
Riccardo Moia Italy 9 108 0.9× 56 0.5× 40 0.7× 41 0.7× 105 2.7× 33 215
María-Jesús Artiga Spain 7 152 1.2× 98 0.9× 32 0.5× 74 1.3× 77 2.0× 7 243
Sunhee S. Kim United States 7 94 0.7× 141 1.2× 39 0.7× 76 1.4× 54 1.4× 12 237
Rebecca Jaslow United States 7 109 0.9× 208 1.8× 120 2.0× 47 0.8× 48 1.2× 20 291
Lijun Shen China 6 148 1.2× 139 1.2× 31 0.5× 87 1.6× 32 0.8× 13 265
Jan Konrad Siwicki Poland 10 76 0.6× 73 0.6× 84 1.4× 142 2.5× 34 0.9× 25 260

Countries citing papers authored by Stefan Alig

Since Specialization
Citations

This map shows the geographic impact of Stefan Alig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Alig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Alig more than expected).

Fields of papers citing papers by Stefan Alig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Alig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Alig. The network helps show where Stefan Alig may publish in the future.

Co-authorship network of co-authors of Stefan Alig

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Alig. A scholar is included among the top collaborators of Stefan Alig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Alig. Stefan Alig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strati, Paolo, Lei Feng, Jason R. Westin, et al.. (2025). Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. Nature Communications. 16(1). 7300–7300.
2.
Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2025). Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Journal of Clinical Oncology. 43(34). 3652–3661.
3.
Alig, Stefan, Bjoern Chapuy, Daisuke Ennishi, Kieron Dunleavy, & Daniel J. Hodson. (2024). Evolving molecular classification of aggressive B‐cell lymphoma. Histopathology. 86(1). 94–105.
4.
Jiang, Linmiao, Karol Pál, Peter J. Stewart, et al.. (2024). Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials. Leukemia. 38(12). 2675–2684. 4 indexed citations
5.
Goldstein, Jordan, Mark Roschewski, Won-Seog Kim, et al.. (2024). Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL. Blood. 144(Supplement 1). 651–651.
6.
7.
Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2023). MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS. Hematological Oncology. 41(S2). 177–179. 5 indexed citations
8.
Schroers‐Martin, Joseph G., Jurik Mutter, Mohammad Shahrokh Esfahani, et al.. (2023). Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma. Blood. 142(Supplement 1). 528–528.
9.
Johansson, Patricia, Stefan Alig, Julia Richter, et al.. (2023). Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma. Annals of Hematology. 102(12). 3445–3455. 2 indexed citations
10.
Shukla, Navika, Joseph G. Schroers‐Martin, Brian J. Sworder, et al.. (2023). Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas. Blood Advances. 8(3). 780–784. 3 indexed citations
11.
Goldstein, Jordan, Won Seog Kim, Sang Eun Yoon, et al.. (2023). Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy. Blood. 142(Supplement 1). 187–187. 7 indexed citations
12.
Krüger, Stephan, Volker Heinemann, Deepak Bararia, et al.. (2021). Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Clinical & Translational Oncology. 23(11). 2394–2401. 13 indexed citations
13.
Haebe, Sarah, Stefan Alig, Michael Heide, et al.. (2021). The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells. British Journal of Haematology. 196(6). 1381–1387. 5 indexed citations
14.
Kurtz, David M., Jacob J. Chabon, Brian J. Sworder, et al.. (2021). Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.. Journal of Clinical Oncology. 39(15_suppl). 8518–8518. 2 indexed citations
15.
Esfahani, Mohammad Shahrokh, Stefan Alig, Mahya Mehrmohamadi, et al.. (2021). Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. Blood. 138(Supplement 1). 37–37.
16.
Alig, Stefan, Vindi Jurinović, Alessandro Pastore, et al.. (2019). Impact of age on clinical risk scores in follicular lymphoma. Blood Advances. 3(7). 1033–1038. 15 indexed citations
17.
Sworder, Brian J., David M. Kurtz, Charles Macaulay, et al.. (2019). Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. Blood. 134(Supplement_1). 550–550. 14 indexed citations
18.
Alig, Stefan, Joachim Pircher, Erik Gaitzsch, et al.. (2015). The Tyrosine Phosphatase SHP-1 Regulates Hypoxia Inducible Factor-1α (HIF-1α) Protein Levels in Endothelial Cells under Hypoxia. PLoS ONE. 10(3). e0121113–e0121113. 20 indexed citations
19.
20.
Mannell, Hanna, Joachim Pircher, Stefan Alig, et al.. (2011). ARNO regulates VEGF-dependent tissue responses by stabilizing endothelial VEGFR-2 surface expression. Cardiovascular Research. 93(1). 111–119. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sebastian Ziegler Breakdown of academic impact, for papers by Hilka Rauert‐Wunderlich Breakdown of academic impact, for papers by Chelsea Mullins Breakdown of academic impact, for papers by Álvaro Eguileor Breakdown of academic impact, for papers by Riccardo Moia Breakdown of academic impact, for papers by María-Jesús Artiga Breakdown of academic impact, for papers by Sunhee S. Kim Breakdown of academic impact, for papers by Rebecca Jaslow Breakdown of academic impact, for papers by Lijun Shen Breakdown of academic impact, for papers by Jan Konrad Siwicki
Rankless by CCL
2026